DHA
Omega-3 Fatty Acid
PI: Michael Rafii, M.D., Ph.D.
This study will determine whether DHA, an Omega-3 fatty acide supplement, can slow the progression of cognitive and functional decline over an 18-month period in patients with mild-to moderate AD.
Criteria
-
50 years or older
-
diagnosis of Probably AD
-
MMSE score 14-26
-
stable Health
-
fluent in English or Spanish
-
consumed no more than 200 mg/day of DHA during the past 2 months
-
have a reliable study partner
Study Procedures
Compensation
- participants will receive up to $200 for undergoing the optional lumbar punctures
Passive Immunization AAB-001-102 PI: Jody Corey-Bloom, M.D., Ph.D.
Study sponsored by Elan Pharmaceuticals, Inc. to find out more about eh safety and tolerability of an experimental drug, AAB-001 administered subcutaneously (injected beneath the skin), in individuals with mild to moderate AD. Criteria
-
diagnosis of probable Alzheimer’s disease
-
50-87 years old
-
MMSE score = 14-26
-
appropriate study partner
-
no other neurological disease
-
stable health status and medications
-
no prior participation in experimental immunotherapeutic or vaccines for AD
-
no metal in the body
Study Procedures
-
16 weeks
-
11 visits
-
MRI
-
physical exam
-
memory testing
-
ECG
-
blood work
Compensation
Huperzine A
PI: Jody Corey-Bloom, M.D., Ph.D.
This study is to determine whether or not Huperzine A is beneficial in the treatment of patients with mild to moderate AD. Huperzine A is a natural cholinesterase inhibitor, derived from the Chinese herb Huperzia serrate and is used in China to treat AD.
Criteria
- treatment with Namenda is allowed
Study Procedures
-
24 weeks
-
memory testing
-
2/3 of participants will receive Huperzine A
-
throughout the study 1/3 will receive placebo for the first 16 weeks, followed by Huperzine A for 8 weeks
Compensation
Valproate
PI: Jody-Corey-Bloom, M.D., Ph.D.
This study will determine if long-term treatment with Valproate can delay the onset of behavioral problems such as agitation nor psychosis and/or slow the expected cognitive function decline in individuals with AD
Criteria
-
55 years or older
-
diagnosis of mild to moderate AD (MMSE 10-20)
-
does not have agitation or psychosis
-
not being treated with psychotropic drugs
-
have a reliable study partner
Study Procedures
-
26 months
-
physical exams
-
memory testing
Lecozotan SR 204
PI: Jody-Corey-Bloom, M.D., Ph.D.
This study will determine what effects Lecozotan SR has on individuals with AD. It is an extension study
Criteria
- have a reliable study partner
Study Procedures
Compensation
|
PI: Adam Fleisher, M.D.
This study is testing the safety of injecting a growth factor gene into the brains of people with AD. CERE-110 is a gene transfer drug that has been studied by scientists in laboratory animals and is in its earliest stage of testing in people.
Gene transfer is sometimes called gene therapy; it is a medical technique that involves adding genes to cells so that the body can make a protein to fix a disease.
CERE-110 is an experimental drug that is designed to tell brain cells to produce more of a protein substance that helps nerve cells grow.
Criteria
Study Procedures
-
25 months
-
2 visits prior to the surgery
-
8 visits after the surgery
-
each visit lasts 2-4 hrs.
-
MRI scans
-
PET scans
-
memory testing
-
blood draws
-
2-day inpatient surgery
-
annual visits at culmination of the 25 month study period
Compensation
|
MINA
(Memory Imaging of Normal Aging)
PI: Adam Fleisher, M.D.
This study aims to develop advanced imaging techniques that can identify people at risk for developing Alzheimer’s disease.
Criteria
- healthy individuals 20-35 years old
- no memory complaints
- right-handed
- english is first language
- family members of people with dementia
- no metal in the body
Study Procedures
- 4 visits over 2 months
- participants will receive detailed memory testing and MRI scans.
Compensation
- participants will receive up to $100 for participation
- all study procedures provided at no cost
|
|
|
